GOLDMAN SACHS GROUP INC - AN2 THERAPEUTICS INC ownership

AN2 THERAPEUTICS INC's ticker is and the CUSIP is 037326105. A total of 32 filers reported holding AN2 THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of AN2 THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$481,998
+422.8%
224,185
+690.2%
0.00%
Q1 2024$92,203
-68.0%
28,370
+102.0%
0.00%
Q4 2023$287,803
-13.4%
14,046
-64.1%
0.00%
Q2 2023$332,410
+13.1%
39,107
+100.6%
0.00%
Q1 2022$294,00019,4970.00%
Other shareholders
AN2 THERAPEUTICS INC shareholders Q2 2023
NameSharesValueWeighting ↓
TCG Crossover Management, LLC 1,289,320$10,959,2201.80%
Octagon Capital Advisors LP 720,900$6,127,6500.85%
RA Capital Management 3,773,517$32,074,8950.61%
BVF INC/IL 1,563,963$13,293,6860.37%
Monashee Investment Management LLC 181,995$1,546,9580.37%
Avidity Partners Management LP 657,200$5,586,2000.20%
Y-Intercept (Hong Kong) Ltd 14,040$119,3400.01%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 27,500$233,7500.01%
Alyeska Investment Group, L.P. 98,426$836,6210.01%
JANUS HENDERSON GROUP PLC 1,000,068$8,590,5780.01%
View complete list of AN2 THERAPEUTICS INC shareholders